Endosense, founded in 2003 and based in Geneva, is developing a Force Sensor ablation catheter intended to provide physicians with an objective, real-time measure of contact between the catheter and the beating heart wall. The product aims to improve the safety and efficacy of percutaneous catheter ablation and to increase adoption of the procedure for treating atrial fibrillation. Management changes include the appointment of Eric Le Royer as CEO and CTO Giovanni Leo on the board; Dina Chaya of 3i and Claudio Nessi of NeoMed also joined the board following the financing. The company positions its catheter as a potential breakthrough that could drive wider international adoption of ablation therapy. Endosense states the technology could help capture a market that analysts project may exceed a billion dollars in sales over the next decade. The company completed a CHF 26 million (USD 20 million) financing to support bringing the technology to market. Endosense is a medical‑technology company that pioneered contact‑force measurement in catheter ablation and developed the TactiCath, the first force‑sensing ablation catheter providing real‑time, objective contact‑force data. The company focuses on improving the efficacy, safety and accessibility of catheter ablation procedures for cardiac arrhythmias. Proceeds from its Series C will support development of its pipeline and the roll‑out of the TactiCath® Quartz contact‑force sensing ablation catheter in Europe via a new direct sales force. Endosense is also advancing a program to gain access to the U.S. market, where the TactiCath is currently an investigational device. Financially, the company has completed multiple Series C closings totaling USD 44.6 million (CHF 41.4 million). Endosense was founded in Geneva in 2003 and is backed by a syndicate of investors including Edmond de Rothschild Investment Partners, Neomed, Gimv, VI Partners, Sectoral Asset Management, Ysios Capital Partners, Initiative Capital Romandie and NGN Capital. Endosense is a Swiss medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias. Its core product is the proprietary force-sensing ablation catheter, the TactiCath. The Geneve-based company announced it received US$36m in Series B financing. The company will use the proceeds to fund European commercialization and a U.S. Premarket Approval (PMA) clinical study of the TactiCath. The financing is intended to support regulatory and commercialization activities for the device in Europe and the U.S.

Total raised

$70M

Funding rounds

3

Latest round

Equity

Latest activity

Nov 2024